A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy
- 29 May 2009
- journal article
- research article
- Published by Elsevier BV in Vaccine
- Vol. 27 (43), 6088-6094
- https://doi.org/10.1016/j.vaccine.2009.05.016
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cellsJCI Insight, 2008
- Therapeutic Immunization with Human Immunodeficiency Virus Type 1 (HIV-1) Peptide-Loaded Dendritic Cells Is Safe and Induces Immunogenicity in HIV-1-Infected IndividualsClinical and Vaccine Immunology, 2008
- Robust CD4+ and CD8+ T cell responses to SIV using mRNA‐transfected DC expressing autologous viral AgEuropean Journal of Immunology, 2007
- Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8+ T cell responsesThe Journal of Experimental Medicine, 2007
- Phase 2 Study of an HIV-1 Canarypox Vaccine (vCP1452) Alone and in Combination With rgp120JAIDS Journal of Acquired Immune Deficiency Syndromes, 2007
- A Randomized, Partially Blinded Phase 2 Trial of Antiretroviral Therapy, HIV‐Specific Immunizations, and Interleukin‐2 Cycles to Promote Efficient Control of Viral Replication (ACTG A5024)The Journal of Infectious Diseases, 2006
- High‐Dose Recombinant Canarypox Vaccine Expressing HIV‐1 Protein, in Seronegative Human SubjectsThe Journal of Infectious Diseases, 2005
- Preparation of Clinical‐Grade Recombinant Canarypox–Human Immunodeficiency Virus Vaccine–Loaded Human Dendritic CellsThe Journal of Infectious Diseases, 2002
- Safety and Immunogenicity of ALVAC vCP1452 and Recombinant gp160 in Newly Human Immunodeficiency Virus Type 1-Infected Patients Treated with Prolonged Highly Active Antiretroviral TherapyJournal of Virology, 2002
- Memory Cytotoxic T Lymphocyte Responses in Human Immunodeficiency Virus Type 1 (HIV-1)-Negative Volunteers Immunized with a Recombinant Canarypox Expressing gp160 of HIV-1 and Boosted with a Recombinant gp160The Journal of Infectious Diseases, 1996